The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

The present invention provides a limb bud mesenchymal cell population, which is derived from mammalian lateral plate mesoderm cells, and is PRRX1 protein-positive.

The invention relates to a method for detecting residual, undifferentiated pluripotent stem cells (PSCs) in a culture of cells differentiated from PSCs, the method comprising: culturing the cells on a substrate coated with laminin-521 and E-cadherin in a medium comprising a ROCK inhibitor; quantitating in the cultured cells expression of a marker of residual, undifferentiated PSCs; and comparing the marker expression in the cultured cells with the marker expression in a reference culture of cells comprising a known proportion of PSCs, wherein lower marker expression in the culture of cells than marker expression in the reference culture of cells indicates absence of residual, undifferentiated PSCs in the cultured cells or presence of residual, undifferentiated PSCs in the cultured cells at a proportion lower than the known proportion of PSCs in the reference culture of cells. The invention also relates to a method for manufacturing a therapeutic composition and a method for treating or preventing a condition in a subject.

One aspect of the present disclosure can include a priming medium for creating an isolated population of stem cells having an anti-inflammatory phenotype from an unprimed population of stem cells. The priming media can include a serum-free medium, a functional activator of a Type I interferon (IFN) pathway and a Type II IFN pathway, and at least two pro-inflammatory cytokines. The functional activator and the at least two pro-inflammatory cytokines can be present in an amount sufficient to promote induction of stem cells having an anti-inflammatory phenotype. The cells having an anti-inflammatory phenotype can be marked by increased expression and/or secretion of one or more anti-inflammatory or immune modulatory mediators as compared to the unprimed population of stem cells. Other aspects of the present disclosure can include stem cells made according to the present disclosure as well as therapeutic compositions and uses of the stem cells.

The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.

The engineered system disclosed herein takes extracted adult stem cells from individual mammal organs (such as adipose fat, bone marrow, or blood) and epigenetically rejuvenates the adult stem cells ex vivo back to a youthful fetal state using chemically defined small molecules. The rejuvenated multipotent stem cells are then exponentially expanded ex vivo in an automated bioreactor under novel conditions that maintain the youthful stem cell function while greatly reducing the risks of producing cancer stem cells. In another variation, this engineered system can also include improving the genetics of autologous adult stem cells using CRISPR base editing of genes affecting all-cause morbidity or mortality or genetic mutations. With or without gene editing, rejuvenated autologous multipotent stem cells are then reintroduced back into an organ or injected systemically into the circulation or bone marrow. The engineered system also includes small molecule treatment of the mammal around the time of stem cell injection to promote tissue regeneration and stem cell engraftment. The engineered system has the potential to promote overall health and longer life expectancy in humans, cats, dogs, and other mammals. The rejuvenated stem cell and small molecule systems offer the potential to treat a wide variety of diseases and disorders such as heart failure, kidney disease, Chronic Pulmonary Disease, frailty, various cancers, rare genetic diseases via CRISPR treated stem cells, and brain diseases such as Alzheimer's, Parkinson's, and vascular dementia. The engineered system treatment with rejuvenated stem cells also has the potential to reverse aging and reduce mortality in humans, dogs, cats, and horses.

The present invention relates to the field of cell therapy, and specifically relates to a method for producing a mesenchymal stem cell population, the mesenchymal stem cell population and a culture supernatant thereof produced by the method, and a pharmaceutical composition containing such cells or the culture supernatant thereof. The present invention further relates to use of the mesenchymal stem cell population and the culture supernatant thereof for preventing and treating diseases.

A cell proliferation inhibitor may include glutamic acid, and a method for regulating the proliferation of cells may use the same.

The present disclosure provides a method of producing a population of lyophilized cells, comprising: (a) freezing a composition comprising a population of cells, an aqueous component, a polyol, a sugar, and a polysaccharide; and (b) removing at least 90% of the aqueous component from the frozen composition to produce the population of lyophilized cells. On some embodiments, the disclosure provides a method of producing a population of reconstituted viable cells, comprising: (a) freezing a composition comprising a population of cells, an aqueous component, a polyol, a sugar, and a polysaccharide; (b) removing at least 90% of the aqueous component from the frozen composition to produce the population of lyophilized cells, and (c) resuspending the population of lyophilized cells in a reconstitution agent to form a reconstituted composition, wherein at least 1% of the cells are viable.

Provided is a cell culture sheet. A cell culture sheet according to an embodiment of the present invention includes: a fiber web which has a 3-dimensional network structure formed through the accumulation of support fibers having an average diameter of at most 1.5 μm, and has a basis weight of 1 to 15 g/m.sup.2; and a functional coating layer which is coated on the support fibers exposed on at least one surface of the fiber web, and has a function of promoting one or more of the adhesion, movement, proliferation, and differentiation of cells. Accordingly, cell adhesion is improved due to the large specific surface area and the surface morphology suitable for cells, and the adhered cells are stably supported. Moreover, the cells can be cultured at high density at a high culture efficiency, and can be cultured and recovered without agglomeration caused by forming a thin film.